Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 1
2016 3
2017 1
2018 1
2019 3
2020 4
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Ray KK, et al. Among authors: wijngaard plj. N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187462 Clinical Trial.
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Raal FJ, et al. Among authors: wijngaard plj. N Engl J Med. 2020 Apr 16;382(16):1520-1530. doi: 10.1056/NEJMoa1913805. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32197277 Clinical Trial.
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Koenig W, Leiter LA, Landmesser U, Schwartz GG, Friedman A, Wijngaard PLJ, Garcia Conde L, Kastelein JJP; ORION Phase III Investigators. Wright RS, et al. Among authors: wijngaard plj. J Am Coll Cardiol. 2021 Mar 9;77(9):1182-1193. doi: 10.1016/j.jacc.2020.12.058. J Am Coll Cardiol. 2021. PMID: 33663735 Free article.
Corrigendum to "Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys" [Toxicology and Applied Pharmacology 443 (2022) 115978].
Lehoux D, Far AR, Kallend D, Wijngaard PLJ, Zerler B. Lehoux D, et al. Among authors: wijngaard plj. Toxicol Appl Pharmacol. 2022 Sep 15;451:116144. doi: 10.1016/j.taap.2022.116144. Epub 2022 Jul 1. Toxicol Appl Pharmacol. 2022. PMID: 35780943 No abstract available.
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
Hovingh GK, Lepor NE, Kallend D, Stoekenbroek RM, Wijngaard PLJ, Raal FJ. Hovingh GK, et al. Among authors: wijngaard plj. Circulation. 2020 Jun 2;141(22):1829-1831. doi: 10.1161/CIRCULATIONAHA.119.044431. Epub 2020 Jun 1. Circulation. 2020. PMID: 32479195 No abstract available.
16 results